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Summary
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) dif-
fers substantially from other idiopathic interstitial pneu-
monias regarding disease trajectory and the appropriate
management strategies, making meticulous diagnosis es-
sential. However, patient characteristics and clinical prac-
tice vary between clinical trials, and real life and registries
provide the opportunity to critically analyse current clinical
practices in order to ultimately improve patient care.
: METHODS: We aimed to identify characteristics of our
baseline IPF cohort at initiation of a web-based registry
for patients with idiopathic interstitial pneumonia. Baseline
and 6-month follow-up data from all consecutive IPF pa-
tients consulting at our centre over 2 years were analysed.
RESULTS: Forty IPF patients were included for baseline
and 23 for longitudinal analysis. Besides many similarities
to other IPF populations, our cohort included considerably
fewer women. Forced vital capacity impairment in our co-
hort was more severe and mortality prediction poorer than
in clinical trials, which emphasises the importance to con-
firm the applicability of clinical trial results with data from
real life settings.
CONCLUSION: Registries for rare diseases such as IPF
are a valuable resource for studying the course of the dis-
ease under current compliance with diagnostic and treat-
ment guidelines and to appreciate local epidemiological
particularities.
Key words: idiopathic interstitial pneumonia, idiopathic
pulmonary fibrosis, registry, real life practice, gender dif-
ferences, cohort study
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most frequent
and severe form of idiopathic interstitial pneumonia (IIP)
[1, 2]. Prompt and correct diagnosis of IPF is crucial,
since antifibrotic drugs are approved for IPF only and its
management differs from that of non-IPF IIPs [3, 4]. Al-
though guidelines and national recommendations for di-
agnosis and treatment are available, real-life standards of-
ten diverge and information about regional discrepancies is
sparse [5–8]. Specifically, in rare diseases, critical review
of current standards by use of registry data can elucidate
clinical reality and guide real-life practices.
The aim of this brief communication is to report charac-
teristics of our baseline IPF cohort revealed at initiation of
our web-based registry for patients with IIP.
Methods and results
We retrospectively analysed all consecutive IPF patients
consulting at our Swiss reference centre over 2 years. Clin-
ical data were collected and stored directly by means of
electronic case report forms, with automatic plausibility
checks, on a web-based platform (ALABUS®, Alabus AG,
Zug, Switzerland).
Data on demographics, risk factors, comorbidities, medica-
tion, symptoms, physical examinations, pulmonary func-
tion tests, 6-minute walk tests, arterial blood gas analysis,
chest computed tomography (CT) scans, bronchoscopy
(including bronchoalveolar lavage), surgical lung biopsy,
multidisciplinary discussion and current therapy (including
oxygen) were assessed. For the 6-month longitudinal ob-
servation, we collected those parameters again, plus rate
of hospitalisations, exacerbations, and death. Approval by
the local ethics committee was obtained for data acqui-
sition (Swiss Ethics Committee, Bern, approval number
KEK 246/15 PB_2016-01524).
Forty patients met the inclusion criteria. Longitudinal data
6 months after the first data entry were available for 23 pa-
tients. Seventeen patients were referred only for a second
opinion or were lost to follow up for other reasons. Patient
characteristics including exposures, symptoms at presenta-
tion, diagnostic tests, comorbidities and ILD severity are
reported in table 1.
Discussion
Interestingly, we found, that our IPF patients were almost
exclusively men (98%), whereas other studies report a pro-
portion of male patients ranging from 57% in Northern
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Italy, to 78% in Germany [9–17]. Compared with women,
men are at greater risk of developing IPF, and have faster
disease progress and an increased mortality [2, 18, 19].
Traditionally men more frequently chose occupations that
are associated with dust exposures. Exposure to agricultur-
al, wood, stone and several metal dusts has been shown
to increase IPF risk, more so in male smokers [20, 21].
Table 1: Patient characteristics at baseline including pulmonary func-
tion tests at follow-up.
Sex, male 39 (98)
Race, Caucasian 37 (88)
Demographics
Age, years 70 (43 to 85)
Ever smokers 32 (80)
Smoked pack-years 32.9 ± 16.6
Farming 4 (10)
Welding 4 (10)
Asbestos 4 (10)
Birds (droppings/feath-
er)
3 (7.5)
Exposures
Dust 2 (5)
Dyspnoea only 8 (20)
Cough only 8 (20)
Symptoms
Dyspnoea and cough 19 (47.5)
Multidisciplinary dis-
cussion
20 (50)
Bronchoalveolar
lavage
19 (48)
Transbronchial biopsy 6 (15)
Investigations
Surgical lung biopsy 19 (48)
GAP Index 4.45 ± 1.72
GAP Stage I 10 (26.3)
GAP Stage II 20 (52.6)
Composite In-
dex
GAP Stage III 8 (21.1)
Lung cancer 3 (7.5)
Pulmonary hyperten-
sion
7 (17.5)
Pulmonary embolism 3 (7.5)
Arterial hypertension 13 (32.5)
Coronary artery dis-
ease
12 (30)
Obesity 10 (25)
Obstructive sleep ap-
noea
9 (22.5)
Gastroesophageal re-
flux
8 (20)
Comorbidities
Depression 2 (5)
Baseline Follow-up p-value#
FVC, L 2.60 ±
0.83
2.46 ± 0.82 0.09
FVC, % predict-
ed
65.1 ±
17.4
60.5 ± 16.9 0.12
FEV1, L 2.17 ±
0.67
2.08 ± 0.68 0.05
FEV1, % pre-
dicted
70.7 ±
18.4
66.3 ± 18.6 0.09
FEV1/FVC, % 84.1 ±
5.2
85.1 ± 7.2 0.58
DLCO 3.89 ±
1.6
3.69 ± 1.2 0.09
DLCO, % pre-
dicted
43.3 ±
17.9
40.7 ± 11.2 0.12
DLCO = diffusion capacity of the lung for carbon monoxide (ml/min/mm
Hg/l); FVC = forced vital capacity; FEV1 = forced expiratory volume in
1 second; GAP = gender, age, physiology (FVC, DLCO) Data are pre-
sented as n (%) or mean ± standard deviation/median (range) * Pul-
monary function data from our clinic available for 38 patients (2 tested
externally). # Paired t-test comparing baseline and 6-month follow-up in
23 patients with available data
Nearly half of our patients reported occupational exposures
and the majority were previous smokers. In Switzerland
even now 30% of men and 24% of women smoke [22],
although in the past this gender difference was more pro-
nounced. Besides these exposure differences between gen-
ders, there are diverging theories hypothesising that the
male predominance in IPF is due to differences in sex hor-
mones, which has also been suggested by animal studies
using the bleomycin model of lung fibrosis [23]. So far,
no clinical studies on sex hormones as modulators of pul-
monary fibrosis in humans are available. However, evi-
dence on sex hormone receptor expression in fibrotic lung
tissue is evolving [24]. The reason for the small number
of women in our IPF population remains unclear; possi-
ble explanations are a regional underdiagnosis [25] or a
more thorough exclusion of secondary causes of interstitial
lung disease in women. Reasons for sex differences in IPF
prevalence warrant further investigation.
Our IPF population had more severe lung function impair-
ment (mean forced vital capacity [FVC] 65% predicted)
compared with other registries and large clinical trial co-
horts (FVC 71–82% predicted) [3, 9, 11, 26, 27]. Com-
pared with our and other registries [9], the populations of
the phase III pharmacological trials included more patients
with GAP stage I (40%) and fewer with GAP stage III
(9%) (GAP score based on gender, age, physiology) [26].
This indicates that patients in clinical trials have less se-
vere disease and better prognosis compared with real life,
and might suggest that our patients were diagnosed at lat-
er disease stages. Clinical trials on safety and efficacy of
antifibrotic agents in real-world settings are emerging [28,
29] and further studies will hopefully confirm the benefit
of antifibrotic medications in the general IPF population.
Age- and smoking-related comorbidities in IPF are highly
prevalent and their management is challenging [30]. Co-
morbidities have a significant impact on quality of life,
morbidity, and mortality, and even though IPF is a fatal
disease every fifth IPF patient dies from unrelated causes
[31]. In contrast to our observations, studies that specifi-
cally screen for comorbidities in their populations report
higher prevalences [30, 32–37], which highlights the im-
portance of specific screening in populations at risk.
We diagnose IPF according to the current ATS/ERS guide-
lines [5] and as previously described in our interstitial lung
disease centre [38]. We found only 50% of our IPF cas-
es were diagnosed by formal multidisciplinary team dis-
cussion. Even though this team approach is considered the
gold standard for diagnosis [5, 6], in real-life practice it is
still implemented poorly with only about 20% of cases di-
agnosed in multidisciplinary conferences [9, 11]. Possible
reasons are the high demand on time and resources, and
the current lack of clear guidance on the format of an ideal
multidisciplinary team discussion [38–40].
Conclusion
We briefly summarised initial data from our local IPF
cohort and the pilot study for an open-end, multicentre
prospective observational cohort study including patients
with IIP referred to specialised centres in Switzerland. Our
data show that patient characteristics, diagnostic standards
and treatments are mostly, but not in every aspect, con-
sistent with international data and recommendations. Most
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strikingly, there are almost no women diagnosed with IPF
in our cohort. Registries for rare diseases offer opportu-
nities to evaluate the real-life situation and contribute to
more effective care for our patients.
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